Danaher Corporation (DHR) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $175.31 (-2.03%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 17, 2026 | Catherine Ramsey Schulte | Robert W. Baird | $249.00 | +42.0% |
| Jan 28, 2026 | Vijay Kumar | Evercore ISI | $254.00 | +44.9% |
| Jan 5, 2026 | Vijay Kumar | Evercore ISI | $250.00 | +42.6% |
| Jul 11, 2025 | Sung Ji Nam | Scotiabank | $275.00 | +56.9% |
| Apr 23, 2025 | Dan Leonard | UBS | $240.00 | +36.9% |
| Apr 22, 2025 | Matthew Sykes | Goldman Sachs | $240.00 | +36.9% |
| Apr 16, 2025 | Catherine Ramsey Schulte | Robert W. Baird | $231.00 | +31.8% |
| Jan 15, 2025 | Matthew Sykes | Goldman Sachs | $250.00 | +42.6% |
| Dec 19, 2024 | Subbu Nambi | Guggenheim | $275.00 | +56.9% |
| Oct 31, 2024 | Doug Schenkel | Wolfe Research | $285.00 | +62.6% |
| Oct 23, 2024 | Paul Knight | KeyBanc | $310.00 | +76.8% |
| Oct 23, 2024 | Catherine Schulte | Robert W. Baird | $277.00 | +58.0% |
| Oct 23, 2024 | Puneet Souda | Leerink Partners | $275.00 | +56.9% |
| Oct 1, 2024 | Jacob Johnson | Stifel Nicolaus | $315.00 | +79.7% |
| Apr 23, 2024 | Justin Bowers | Deutsche Bank | $270.00 | +54.0% |
| Apr 17, 2024 | Rajesh Kumar | HSBC | $280.00 | +59.7% |
| Sep 27, 2023 | Paul Knight | Loop Capital Markets | $300.00 | +71.1% |
| Jul 31, 2022 | Elizabeth Garcia | UBS | $297.00 | +69.4% |
| Jun 1, 2022 | Deane Dray | RBC Capital | $310.00 | +76.8% |
| May 6, 2022 | Catherine Schulte | Robert W. Baird | $319.00 | +82.0% |
Top Analysts Covering DHR
DHR vs Sector & Market
| Metric | DHR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.24 | 2.41 |
| Analyst Count | 14 | 8 | 18 |
| Target Upside | +40.9% | +1150.2% | +14.9% |
| P/E Ratio | 33.91 | 6.84 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $25.30B | $25.48B | $25.59B | 16 |
| 2027-03-27 | $6.27B | $6.31B | $6.34B | 11 |
| 2027-03-31 | $6.21B | $6.32B | $6.43B | 6 |
| 2027-06-27 | $6.43B | $6.47B | $6.51B | 11 |
| 2027-06-30 | $6.39B | $6.51B | $6.61B | 6 |
| 2027-09-27 | $6.57B | $6.61B | $6.65B | 11 |
| 2027-09-30 | $6.51B | $6.62B | $6.73B | 6 |
| 2027-12-27 | $7.51B | $7.56B | $7.60B | 11 |
| 2027-12-31 | $26.58B | $27.01B | $29.06B | 16 |
| 2028-03-27 | $6.50B | $6.54B | $6.58B | 5 |
| 2028-03-31 | $6.47B | $6.58B | $6.69B | 6 |
| 2028-06-27 | $6.66B | $6.70B | $6.74B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.39 | $8.44 | $8.54 | 13 |
| 2027-03-27 | $2.15 | $2.17 | $2.18 | 6 |
| 2027-03-31 | $2.05 | $2.10 | $2.14 | 10 |
| 2027-06-27 | $2.00 | $2.02 | $2.04 | 12 |
| 2027-06-30 | $2.02 | $2.06 | $2.11 | 6 |
| 2027-09-27 | $2.17 | $2.18 | $2.20 | 6 |
| 2027-09-30 | $2.17 | $2.23 | $2.27 | 7 |
| 2027-12-27 | $2.66 | $2.69 | $2.71 | 10 |
| 2027-12-31 | $8.99 | $9.10 | $9.25 | 12 |
| 2028-03-27 | $2.24 | $2.26 | $2.28 | 11 |
| 2028-03-31 | $2.15 | $2.20 | $2.24 | 7 |
| 2028-06-27 | $2.08 | $2.10 | $2.12 | 7 |
Frequently Asked Questions
What is the analyst consensus for DHR?
The consensus among 14 analysts covering Danaher Corporation (DHR) is Buy with an average price target of $253.75.
What is the highest price target for DHR?
The highest price target for DHR is $370.00, set by Katie Tryhane at Credit Suisse on 2021-09-10.
What is the lowest price target for DHR?
The lowest price target for DHR is $231.00, set by Catherine Ramsey Schulte at Robert W. Baird on 2025-04-16.
How many analysts cover DHR?
14 analysts have issued ratings for Danaher Corporation in the past 12 months.
Is DHR a buy or sell right now?
Based on 14 analyst ratings, DHR has a consensus rating of Buy (2.14/5) with a +40.9% upside to the consensus target of $253.75.
What are the earnings estimates for DHR?
Analysts estimate DHR will report EPS of $8.44 for the period ending 2026-12-31, with revenue estimated at $25.48B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.